血清D-二聚体、降钙素原水平对采用连续肾脏替代疗法治疗的脓毒症伴急性肾损伤患者预后的预测价值分析

Abstract
Figure/Table
References (15)
Related Citation (15)

Download: PDF (0 KB) HTML (31 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To investigate the predictive value of serum D-dimer (D-D) and procalcitonin (PCT) levels in prognosis of patients with pyemia and acute kidney injury treated with continuous renal replacement therapy (CRRT).Methods The clinical data of 168 patients with pyemia and acute kidney injury who were treated with CRRT in Peking University Shougang Hospital from January 2015 to December 2020 were retrospectively analyzed. According to the prognosis of the patients, they were divided into the good prognosis group (n=108) and the poor prognosis group (n=60).Serum D-D and PCT levels of the patients were statistically analyzed for the prognostic value of serum D-D and PCT levels in patients. Results The serum levels of D-D and PCT in the poor prognosis group were higher than those in the good prognosis group (P＜0.05). According to the multiple logistic regression analysis, the high serum D-D and PCT levels were the risk factors for poor prognosis in patients with pyemia complicated with acute kidney injury (P＜0.05).Receiver operating characteristic curve (ROC) results showed that serum D-D and PCT levels before treatment predicted the poor prognosis of emergency CRRT patients with pyemia and acute kidney injury with the AUC of ＞0.70, which had ideal predictive value, and the combined predictive value was the best. Conclusion Serum D-D and PCT levels have certain value in predicting the prognosis of patients with pyemia and acute kidney injury after CRRT treatment.

Key words： Pyemia Acute kidney injury Continuous renal replacement therapy D-dimer Procalcitonin

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	CHENG Jie
	CHEN Xin

Cite this article:

CHENG Jie,CHEN Xin. Analysis on predictive value of serum D-dimer and procalcitonin levels in prognosis of patients with pyemia and acute kidney injury treated with continuous renal replacement therapy[J]. 中国当代医药, 2021, 28(30): 64-67.

URL:

http://dangdaiyiyao.com/EN/ OR http://dangdaiyiyao.com/EN/Y2021/V28/I30/64

[1]	杨婷婷，周瑞祥，姚慧，等.连续性肾脏替代治疗时机选择对脓毒症急性肾损伤患者预后的影响[J].现代仪器与医疗，2019，25（5）：11-15.
[2]	杨晓梅，杭敏，许磊，等.脓毒症患者血清ESM-1、D-D、miR-155-5p、PCT 的变化与患者预后的关系[J].医学临床研究，2019，36（4）：759-761.
[3]	黄辉权.PCT、SCr、BUN 与脓毒症合并急性肾损伤患者的关系[J].医学临床研究，2020，37（1）：111-113.
[4]	中华医学会重症医学分会.中国严重脓毒症/脓毒性休克治疗指南（2014）[J].中华内科杂志，2015，54（6）：557-581.
[5]	急性肾损伤专家共识小组.急性肾损伤诊断与分类专家共识[J].中华肾脏病杂志，2006，22（11）：661-663.
[6]	Seymour CW，Liu VX，Iwashyna TJ，et al.Assessment of Clinical Criteria for Sepsis：For the Third International Consensus Definitions for Sepsis and Septic Shock （Sepsis-3）[J].JAMA，2016，315（8）：762-774.
[7]	王涛，何朝霞，朱长亮.脓毒症合并急性肾损伤不同血液净化时机的临床回顾性研究[J].中国临床保健杂志，2019，22（5）：690-693.
[8]	李凤月.血清PCT、CRP 联合血浆D-二聚体检测在肺炎合并脓毒症患儿中的诊断意义[J].解放军预防医学杂志，2018，36（12）：1557-1559.
[9]	廖宴，戴娟，黄文龙，等.不同分级及转归脓毒症患者血清PCT、D-D、CRP 及血小板相关参数检测的临床意义[J].现代生物医学进展，2020，20（18）：3452，3453-3456.
[10]	胡晓宁，耿静，郎哲，等.血清NGAL 和PCT 对脓毒症相关急性肾损伤的评估及临床意义的研究[J].临床急诊杂志，2020，21（9）：696-700.
[11]	梁维，赵静，冯玲，等.脓毒症合并早期急性肾损伤患者sTREM-1、Ang-2 及PCT 水平变化及其与预后相关性分析[J].解放军医药杂志，2020，32（1）：60-63.
[12]	黄莉莉，缪华杰，陆洋，等.脓毒症患者血清胱抑素C、尿液肾脏损伤分子1 水平变化及其对并发急性肾损伤的诊断价值[J].山东医药，2017，57（31）：70-72.
[13]	路坤，何先弟，汪华学，等.脓毒症相关急性肾损伤在连续肾替代治疗早期降钙素原的预测价值[J].蚌埠医学院学报，2020，45（1）：60-63.
[14]	刘名胜，邢柏.脓毒症性与非脓毒症性急性肾损伤行CRRT 治疗患者临床特征及预后影响因素对比分析[J].山东医药，2020，60（14）：60-64.
[15]	马鸿雁，许颖，刘丽.早期连续性肾脏替代治疗脓毒症并发急性肾损伤3 期患者的疗效分析[J].中华医院感染学杂志，2020，30（17）：2642-2646.